Harrow Health Inc (HROW)vsUnited Therapeutics Corporation (UTHR)
HROW
Harrow Health Inc
$33.07
-0.09%
HEALTHCARE · Cap: $1.41B
UTHR
United Therapeutics Corporation
$475.45
+0.69%
HEALTHCARE · Cap: $21.22B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 1045% more annual revenue ($3.15B vs $275.59M). UTHR leads profitability with a 41.6% profit margin vs -13.5%. UTHR earns a higher WallStSmart Score of 61/100 (C+).
HROW
Avoid23
out of 100
Grade: F
UTHR
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HROW.
Margin of Safety
+0.8%
Fair Value
$479.67
Current Price
$475.45
$4.22 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 42.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 20 in profit
Attractively priced relative to earnings
Areas to Watch
Smaller company, higher risk/reward
Trading at 80.7x book value
ROE of -35.4% — below average capital efficiency
Earnings declined 10.3%
Expensive relative to growth rate
Revenue declined 1.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : HROW
Revenue growth of 10.9% demonstrates continued momentum.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.6% and operating margin at 42.2%.
Bear Case : HROW
The primary concerns for HROW are Market Cap, Price/Book, Return on Equity. Debt-to-equity of 19.79 is elevated, increasing financial risk.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
HROW profiles as a turnaround stock while UTHR is a declining play — different risk/reward profiles.
UTHR carries more volatility with a beta of 0.56 — expect wider price swings.
HROW is growing revenue faster at 10.9% — sustainability is the question.
UTHR generates stronger free cash flow (206M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (61/100 vs 23/100), backed by strong 41.6% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Harrow Health Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Harrow Health, Inc. is an ophthalmology-focused healthcare company. The company is headquartered in San Diego, California.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?